The high costs of robotic tech | Medtronic recalls thousands of devices | TAVR in younger patients | FDA approves next-gen valve - Cardiovascular Business
This is an aggregator roundup rather than a primary clinical report, bundling four threads: robotic surgical platform economics, a Medtronic device recall, TAVR use in younger patients, and an FDA next-generation valve approval.
Without the underlying study or regulatory documents in hand, the specific recall scope, valve platform approved, and the younger-patient TAVR dataset cited cannot be verified from this item alone.
The younger-patient TAVR thread is the one that warrants the most circumspection.
Both ACC/AHA 2020 (SAVR preferred <65) and ESC 2025 (SAVR preferred <70 at low surgical risk) explicitly carve out younger patients from the TAVI-first pathway, and the RCT evidence base in patients under 65 remains thin.
The high costs of robotic tech | Medtronic recalls thousands of devices | TAVR in younger patients | FDA approves next-gen valve Cardiovascular Business
- Aortic Valve (TAVR/TAVI)· TCTMD.comLANDMARK: 2-Year Data Show Continued Safety and Efficacy of Unique TAVI Valve - TCTMD.com
- Aortic Valve (TAVR/TAVI)· CNBCJosh Brown's 'best stocks in the market': Edwards Lifesciences - CNBC
- Aortic Valve (TAVR/TAVI)· Investing.com AustraliaEdwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock - Investing.com Australia
- Clinical Trials Update· ClinicalTrials.govREdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
- Clinical Trials Update· ClinicalTrials.govReal World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
- Clinical Trials Update· ClinicalTrials.govNHLBI-Emory Advanced Cardiac CT Reconstruction